Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance

@article{Matthews2010Interleukin6deficientMD,
  title={Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance},
  author={Vance Bruce Matthews and Tamara L. Allen and Steve Risis and M. H. Stanley Chan and Darren C. Henstridge and Nadine Watson and Lee A. Zaffino and Joanne R Babb and James Boon and Peter J. Meikle and Jeremy B. M. Jowett and Matthew J. Watt and John-Olov Jansson and Clinton R. Bruce and Mark A. Febbraio},
  journal={Diabetologia},
  year={2010},
  volume={53},
  pages={2431-2441}
}
Aims/hypothesisThe role of IL-6 in the development of obesity and hepatic insulin resistance is unclear and still the subject of controversy. We aimed to determine whether global deletion of Il6 in mice (Il6−/−) results in standard chow-induced and high-fat diet (HFD)-induced obesity, hepatosteatosis, inflammation and insulin resistance.MethodsMale, 8-week-old Il6−/− and littermate control mice were fed a standard chow or HFD for 12 weeks and phenotyped accordingly.ResultsIl6−/− mice displayed… 
Adipocyte specific deletion of IL-6 does not attenuate obesity-induced weight gain or glucose intolerance in mice.
TLDR
Examination of the role of adipocyte derived IL-6 in a genetic model of obesity and insulin resistance by crossing the AdipoIL-6-/- mice with leptin deficient (ob/ob) mice found it did not contribute to whole body glucose intolerance in obese mice.
Hematological and acute-phase responses to diet-induced obesity in IL-6 KO mice.
Long-term exposure to a high-fat diet results in the development of glucose intolerance and insulin resistance in interleukin-1 receptor I-deficient mice
TLDR
While mature-onset obesity is evident in LFD-IL-1RI−/− mice, the additional metabolic insult of HFD was required to drive adipose inflammation and systemic IR, indicating an important interaction between dietary fat and IL-1, relevant to optimal metabolic health.
Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL‐6 production
TLDR
Novel data suggest that Tnfsf14 ablation exacerbates parameters of the metabolic syndrome under high fat feeding conditions and provides evidence to support the development of TNFSF14 agonists as potential therapeutics in diet‐induced obesity.
Adipose Tissue Insulin Action and IL-6 Signaling after Exercise in Obese Mice.
TLDR
A link between exercise-induced increases in IL-6, reductions in indices of M1 macrophages, and increased IL-10, a reputed anti-inflammatory cytokine with insulin-sensitizing properties is suggested.
Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice
TLDR
The administration of rIL-6 might contribute to the aggravation of fatty liver disease through increasing lipogenesis in HFD-induced obesity.
Interleukin-18 Activates Skeletal Muscle AMPK and Reduces Weight Gain and Insulin Resistance in Mice
TLDR
IL-18 enhances AMPK signaling and lipid oxidation in skeletal muscle implicating IL-18 in metabolic homeostasis and concomitantly inhibited HFD-induced weight gain.
Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice
TLDR
It is indicated that continuous stimulation with IL-6 attenuates the IL- 6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-8-/- mice exposed to DIO and in obese Zucker rats.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Interleukin-6 depletion selectively improves hepatic insulin action in obesity.
TLDR
Results indicate that IL-6 plays an important and selective role in hepatic insulin resistance of obesity, and depletion of IL- 6 improved insulin responsiveness in 2-h insulin tolerance tests.
Human IL6 enhances leptin action in mice
TLDR
Human IL6 enhanced central leptin action in mice, promoting nutrient homeostasis and preventing diet-induced obesity.
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
TLDR
It is shown that lipid accumulation in the liver leads to subacute hepatic 'inflammation' through NF-κB activation and downstream cytokine production, which causes insulin resistance both locally in liver and systemically.
Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity.
TLDR
IL-6 knockout mice do not demonstrate obesity, fasting hyperglycemia, or abnormal lipid metabolism, although HF IL-6(-/-) mice demonstrate elevated glucose after a GTT, and there were no differences in plasma leptin or TNF-alpha due to genotype.
Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice.
TLDR
The data suggest that chronic IL-6 treatment selectively impairs hepatic insulin signaling in vivo, further supporting a role for IL- 6 in hepatics insulin resistance of obesity.
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.
TLDR
It is shown that lipid accumulation in the liver leads to subacute hepatic 'inflammation' through NF-kappaB activation and downstream cytokine production, which causes insulin resistance both locally in liver and systemically.
Mature-Onset Obesity in Interleukin-1 Receptor I Knockout Mice
TLDR
It is concluded that lack of IL-1RI–mediated biological activity causes mature-onset obesity, and this obese phenotype is preceded by decreased leptin sensitivity, fat utilization, and locomotor activity.
Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice
TLDR
Chronically elevated IL-6 levels lead to inappropriate hyperinsulinaemia, reduced body weight, impaired insulin-stimulated glucose uptake by the skeletal muscles and marked inflammation in the liver, despite the fact that weight reduction may be expected.
The role of interleukins in insulin resistance and type 2 diabetes mellitus
TLDR
Experimental and clinical studies now converge to show that several ILs contribute to the pathology and physiology of T2DM through their interaction with insulin signaling pathways and β-cell function.
Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo.
TLDR
This is the first study to demonstrate that inflammatory cytokines IL-6 and IL-10 alter hepatic and skeletal muscle insulin action in vivo, and the mechanism may involve cytokine-induced alteration in intracellular fat contents.
...
1
2
3
4
5
...